Catalent Provides a Simplified Delivery Solution to Speed Clinical Proof of Concept
Somerset, NJ, November 4, 2010 — To help drug development scientists reach their “first dose in man” faster, Catalent Pharma Solutions, LLC has added the Xcelodose® micro-dosing system to its Research Triangle Park (RTP), North Carolina facility. This system provides high-precision metering of powder active pharmaceutical ingredients (API) into capsules, which eliminates the need of upfront formulation activities and minimizes the amount of actives required to manufacture the clinical batch.
Precision powder micro-dosing provides compelling benefits:
• Accurate and reproducible dosing down to as little as 100 micrograms of powder
• Capability of producing small batches less than 100 capsules
• Simplified formulation efforts and reduced drug development timeline
• High quality clinical supplies
• Lower development costs
Catalent is a global leader in oral drug delivery and offers the widest array of drug delivery technologies designed to rapidly advance customers’ projects. The addition of the Xcelodose® system to Catalent’s RTP development site is part of a commitment to meet the needs of its customers.
To learn more about Catalent’s Development and Clinical Services, please visit www.catalent.com/development .
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 29 facilities worldwide and in fiscal 2010 generated more than $1.7 billion in annual revenue. For more information, visit www.catalent.com .
more products. better treatments. reliably supplied.™
XCELODOSE is a registered trademark of Capsugel Belgium BVBA.